{"entity":{"id":"nct03647163","kind":"trial","name":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Ipilimumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Vyriad, Inc., active and no longer recruiting.","summary":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors is a phase 1/2 interventional study registered as NCT03647163 by Vyriad, Inc., with 33 participants enrolled, started 2019-04-09 and due to reach its primary completion in 2025-07-31. Interventions recorded: VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab. Conditions listed: Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03647163","url":"https://clinicaltrials.gov/study/NCT03647163"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","ipilimumab","nivolumab"],"companies":["vyriad"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03647163","phase":"1/2","setting":"Phase 1-2 Trial of Systemically Administered VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selected Solid Tumors","sponsor":"Vyriad, Inc.","enrolled":33,"outcomes":[]},"route":"/trials/nct03647163/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"vyriad","kind":"company","name":"Vyriad","route":"/companies/vyriad/"}]}}